• Reset
23 Dec 2022
Case analysis: Combe International v Dr Wolff

Can adding the company name to a mark avoid infringement?: Lauren Palmer, Legal Assistant at Dehns  provides a case analysis of Combe International v Dr Wolff

15 Dec 2022
Case analysis: Teva UK Ltd and anor v Novartis AG and anor

Arrow declaration misses its target: Paul Harris, Head of Litigation at Dehns, considers the extent to which the Patents Court will go in order to provide a “spin-off value” for one party, in the courts of another jurisdiction.

 

10 Nov 2022
Plausibility at the EPO – An update on G2/21

Dehns have previously discussed the concept of plausibility and how much experimental data is needed for patent applications in Europe, which is relevant to both sufficiency and inventive step. In an ideal world all the relevant data would be contained in the application as filed. However, this is not always possible, particularly if new prior art is found during prosecution that necessitates the formulation of new comparative data to support an inventive step.

01 Nov 2022
Infringement of repurposed drug patents and skinny labelling – where does the balance lie in the United States today?

A balance must be struck between the competing interests of generic and innovator companies to ensure the healthcare system works at its best. At the moment, that longstanding balance has been disrupted by the Federal Circuit and the ripples are still being felt in the generics industry, even if the court has tried to take some of the sting out of its earlier actions.

27 Oct 2022
The IP Podcast – Season 2 Ep. 4: Repurposed drugs and skinny labelling

In this episode of The IP Podcast, Senior Associate Daniel Rowe discusses a topic relating to the biotechnology and pharma industries: repurposed drugs and skinny labelling.

Tune in to hear Dan answer:

  • What are repurposed drugs and why are they important?
  • Can repurposed drugs be patent protected even though the patent covering the original drug may have expired?
  • What is a skinny label?

All these questions and more, answered in less than 20 minutes!

25 Oct 2022
Infringement of repurposed drug patents and skinny labelling – where does the balance lie in Europe today?

The contributions of both generic and innovator companies to our healthcare systems are essential, and a balance must be struck between their competing interests to ensure the system works at its best.

13 Oct 2022
How good does a copy need to be?

Read Neil Campbell’s latest thinking on how far a commercial product placed on the market becomes part of the state of the art.  Neil will be speaking at LSPN in San Francisco on 1 November.

28 Sep 2022
Supplementary Protection Certificates – European Patent Term Extensions

The purpose of patents is to drive innovation. However, many jurisdictions accept that a patent term of 20 years from filing is not always sufficient to compensate an innovator for the expense and risk of developing certain types of product. Many countries in Europe (including the UK despite its exit from the EU) have adopted an alternative approach to compensating for lost patent term. This new right is known as a “Supplementary Protection Certificate” (SPC) and although quite limited in scope, it can provide highly valuable protection since it comes into force at the expiry of the patent and is sharply focused on protecting the commercial produc

21 Sep 2022
How much experimental data is needed for patent applications in Europe?

As many in the life sciences and chemical sectors await the G2/21 decision, Jonathan Bailey, Associate in the Dehns Chemical Group, discusses how much experimental data is needed for patent applications in Europe.

17 Aug 2022
Best practice for invention harvesting

Invention harvesting, or invention mining, is an important process for any company looking to build or expand a patent portfolio.

Subscribe here for updates on IP news, events and webinars.


 I consent to receive updates from Dehns via email